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Besien,5 Seira Kurian,6 Paula del Cerro,5 Juan J. Toro,3 Loretta A. Williams,4
Seth W. Ketelsen,7 Willis H. Navarro,8 J. Douglas Rizzo7Outcome disparity associated with race or ethnicity in the United States has been observed in hematopoietic
cell transplantation (HCT). The underlying reasons for such disparity are not known. In the United States, an
optimal study of health care disparity by race or ethnicity involves consideration of both biologic and psycho-
social determinants, which requires an adequately powered, prospective cohort study design. To better char-
acterize the nature and quantify the magnitude of the many impediments relevant to conducting a successful
prospective study involving racial or ethnic minorities in HCT, we conducted a feasibility study to help guide
planning of a larger scale outcome and disparity study in HCT. The primary questions to be addressed in the
study were: (1) can we establish a racially or ethnically diverse patient sample that will respond to a survey
focused on sociodemographic, economic, health insurance, cultural, spiritual, and religious well-being, and
social support information? (2) What is the retention rate in the study over time? (3) What is the quality
of the data collected from the patients over time? The challenges we faced in conducting this multicenter
feasibility study are summarized in this report. Despite the difficulty in conducting disparity studies in racial
and ethnic minorities, such studies are essential to ensure that people of all ethnic and racial backgrounds
have the best chance possible of benefiting from HCT.
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Outcome disparity associated with race or ethnic-
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6/j.bbmt.2009.04.005medical and surgical procedures. An association be-
tween African American or Hispanic minority status
and outcomes has also been seen among patients
with hematologic malignancies undergoing hemato-
poietic cell transplantation (HCT) [1-4]. Retrospec-
tive analyses of large multicenter data from the
Center for International Blood and Marrow Trans-
plant Research (CIBMTR) showed that, in the setting
of HLA-matched sibling transplantation for acute and
chronic leukemia, Hispanics had a higher risk of treat-
ment failure and overall mortality when compared to
Caucasians [1,2]. A separate analysis of patients treated
at Fred Hutchinson Cancer Research Center demon-
strated a higher risk of mortality for African Americans
when compared to Caucasians [3]. In unrelated HCT,
African Americans and/orHispanics had higher overall
mortality when compared to Caucasians [3,4]. How-
ever, outcome disparities by race or ethnicity are not
seen in autologous transplantation [3,5]. The reasons
for the differential findings in autologous and alloge-
neic procedures and the underlying factors causing out-
come disparity in allogeneic recipients are not known.903
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DISPARITY BY RACE OR ETHNICITY IN HCT
Allogeneic HCT is a complex, high-risk procedure
that is usually offered with curative intent. Its effective-
ness in the treatment of leukemia and lymphoma is be-
lieved to be because of a graft-versus-tumor (GVT)
effect [6]. Variables that can influence outcomes in-
clude both biologic and nonbiologic factors. A key
biologic determinant in outcomes for unrelated alloge-
neic HCT is the degree of human leukocyte antigen
(HLA)-matching between donor and recipient. Ongo-
ing improvements in the characterization of HLA
biology have decreased the risk of graft-versus-host
disease (GVHD) and contributed to improved out-
comes in unrelated donor transplantation in recent
years [7-10]. However, the degree to which HLA
diversity in different races affects outcomes is less clear
because most HLA studies include few minorities.
Many clinical factors associated with race also have
prognostic importance, such as age at disease onset,
cancer cell biology, disease stage at diagnosis, and
comorbid medical conditions.
Multiple nonbiologic factors may also directly or
indirectly affect the clinical outcomes after allogeneic
HCT, with some associated with race or ethnicity.
These factors include: patient socioeconomic status
(SES), health care access (insurance coverage, geo-
graphic barriers, time to acquiring treatment, follow-
up care) and delivery (compliance, treatment options
received), and psychosocial and cultural factors [11-
14]. Ethnic minorities in the United States are more
likely than Caucasians to have lower SES and have in-
adequate medical insurance coverage leading to poor
outcomes [15]. Lower SES is associated with lower
overall health care usage, fewer surveillance tests, and
lower quality ambulatory and hospital care [16]. A sig-
nificantly higher percentage of Hispanics lack ade-
quate medical insurance compared to Whites, Blacks,
and Asians [17]. Other barriers to access and delivery
of health care observed among minority groups, such
as skepticism toward efficacy of treatment [18], lower
satisfaction with health care received [19], and lan-
guage barriers [20] could also potentially affect sur-
vival. Previous studies show that minority children,
including Blacks and Hispanics, make fewer physician
visits compared toWhite children [21]. Little is known
about how follow-up care varies by race or ethnicity
among recipients of complicated treatments, such as
HCT, and how this may affect outcomes. Ethnic dif-
ferences in reacting to and coping with a new state of
health and well-being are not well understood in
HCT, but are linked with survival among patients
with breast cancer [22]. All the above factors may be
accentuated in a procedure such as allogeneic HCT,
where a significant amount of recovery occurs in the
outpatient setting and risks of treatment-relatedcomplications are extremely high and enduring be-
yond the procedure itself.FORMULATING THE STUDY QUESTION AND
APPROPRIATE STUDY DESIGN
Based on past studies in HCT and in the general
medical literature, there are 3 areas that need to be ex-
amined in studies of health disparity by race or ethnic-
ity to establish causality: (1) the race/ethnic group
distinction to use, (2) the biologic determinants to con-
sider, and (3) the psychosocial determinants to explore
including the role of SES. There are no consistent
standard definitions of race or ethnicity in the context
of health-related studies. Definitions are usually study
specific and can either be viewed as an index of biologic
distinction or as an index of social grouping. For the
most part, racial or ethnic distinctions are usually des-
ignated by the patients themselves. This manner of
designation, although acceptable, is truly imprecise,
and is a combination of both biologic and social defini-
tion.
In the United States, any study exploring causes
of health care disparity by race or ethnicity requires
consideration of both biologic and psychosocial deter-
minants and demands an adequately powered, pro-
spective cohort study design. Although retrospective
studies are essential in moving this area of research,
only prospective studies will allow for a comprehensive
assessment of all relevant factors that may explain dis-
parate outcomes. These factors should include both
biologic and nonbiologic entities, such as behavioral
characteristics and individual decision making, and
should cover factors before, during, and after HCT.
Many of the nonbiologic variables cannot be captured
retrospectively or through administrative databases.
The goal of prospective research is to identify areas
where interventions may be targeted. This also allows
for the magnitude of the association between race/eth-
nicity and outcomes to be estimated while controlling
for biologic factors or understanding the complex rela-
tionships among many factors. This also allows for
temporality and plausibility of the relationship to sup-
port ‘‘cause and effect,’’ something retrospective stud-
ies are not able to support with certainty.FEASIBILITYOF STUDYING RACIAL AND
ETHNIC MINORITY PATIENTS
Table 1 summarizes the impediments encountered
in the execution of a prospective cohort study designed
to explore the reason for disparate outcomes by race or
ethnicity.
First is the issue of ability to accrue adequate num-
bers of racial or ethnic minorities. In a study published
Table 1. Study Impediments to Investigate Disparity Study
by Race or Ethnicity in HCT
1. Sample population  Fewer numbers of HCT performed in racial
or ethnic minorities
 Multicenter study inevitable – coordination
issues
2. Historic poor
participation
 Differential participation rate between racial
or ethnic minorities and Caucasians
3. Performance and
study execution
concerns
 Unknown retention rate over time
 Potential language barriers
 Coordination of IRB reviews and different
approaches to handling racial or ethnic
minorities.
 Collectability of patient derived information
encompassing socioeconomic, psychological,
cultural, etc.
HCT indicates hematopoietic stem cell transplantation.
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ters in the United States, racial or ethnic minorities
represented at least 20% of patients undergoing allo-
geneic transplantation. These were considered as
high-minority HCT centers. Additionally, Hispanics
represent 10% or greater of the patient population at
only 24% of U.S. centers. The high-minority centers
also transplanted significantly fewer patients than
low-minority centers (median 40/year versus 66/year)
[23]. This suggests that to acquire an adequate sample
of racial or ethnic minorities, a multicenter study tar-
geting high-minority HCT centers is essential, but
that center differences may confound the analysis.
Second, racial or ethnic minorities are difficult to
recruit. Studies have shown that racial or ethnicminor-
ities are less likely to participate in clinical studies in
general and to HCT studies in particular [24,25]. A
third barrier is a confluence of issues related to study
performance of racial or ethnic minorities over time.
Some of these issues include loss to follow-up, poten-
tial language barriers related to consent procedure, in-
stitutional review board (IRB) approval, survey
questionnaire design, completion rates of various psy-
chometric instruments, and considerations for statisti-
cal analyses because of the nature of sampling bias.
Atlhough most biologic factors are routinely collected
as part of the clinical and research activities performed
by transplant centers, data from patients pertaining to
psychosocial factors are not. To date, even large regis-
tries such as the CIBMTR have not been successful in
obtaining SES and behavioral variables. The ability to
collect this information from racial and ethnic minor-
ities is also not well characterized.
Considering the magnitude of the many potential
impediments relevant to conducting a successful pro-
spective study involving racial or ethnic minorities in
HCT, we conducted a feasibility study to guide the
planning of a larger scale, outcome and disparity study
in HCT. Conducting a feasibility study was crucial be-
cause of increasing concern that racial or ethnicminor-
ities may not participate. Additionally, a feasibilitystudy would allow the researchers to convince funding
agencies that they have a grasp of the potential barriers
to be encountered in a prospective study focused on
modifiable causes of disparity in outcomes. The pri-
mary questions of the study to be addressed were: (1)
can we establish a racially or ethnically diverse patient
sample who will respond to a survey focused on socio-
demographic, economic, health insurance, cultural,
spiritual, and religious well-being; and social support
information? (2)What is the retention rate in the study
over time? (3) What is the quality of the data collected
from the patients over time? The challenges we faced
in conducting this multicenter feasibility study are
summarized below.LESSONS LEARNED
Study Funding
Although in general, well-designed studies of dis-
parity by race or ethnicity are interesting and of suffi-
cient importance to warrant funding at the national
level, the funding of feasibility studies is not as attrac-
tive. After 2 attempts at revising the proposed study
within a period of 18months, the study principal inves-
tigator (F.R.L.) secured a $50,000 grant from theMed-
ical College of Wisconsin through institutional funds
awarded by the American Cancer Society, which
made the study possible.Center Recruitment and Sample Population
The study group met in person during the 2003
Annual Meeting of the American Society for Blood
and Marrow Transplant at Keystone, CO, to discuss
the final study plan and identify a contact person at
each center. Five high-minority centers with at least
20% of total transplants performed in racial or ethnic
minorities were identified. Two centers from Texas
(M.D. Anderson Cancer Center in Houston and South
Texas Veterans Health Care System/University of
Texas Health Science Center at San Antonio) were in-
vited because of a high potential recruitment for His-
panic patients, 1 center in Chicago (University of
Chicago) and another in Milwaukee (Medical College
of Wisconsin) were recruited for their potential for
high African American recruitment, and 1 center in
San Francisco (University of California San Francisco)
was recruited for its potential for high Asian American
recruitment. All centers performed at least 100 HCT
annually. We felt convenience sampling, as opposed
to randomized selection of HCT centers, was accept-
able, because, based on the number ofminorities trans-
planted annually, this is the likely approach we would
adapt in a larger study. The centers also had investiga-
tors who are part of the study group and had the
Table 2b. Projected Accrual if Number of Centers is In-
creased and Study Period Extended
Current Study
Projected Number
of Centers*
Number of centers
recruiting/
3 6 9 12 15 18
Time to enroll Y
6 months 22 44 66 88 110 132
12 months 44 88 132 176 220 264
24 months 88 176 264 352 440 528
*Estimates of ethnic minorities based on recruiting centers who trans-
plant the same volume as the centers in the feasibility study.
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low-up of patients.
The feasibility study was designed to recruit pa-
tients at least 18 years of age who were undergoing re-
lated or unrelated allogeneic HCT. The enrollment
period was 6 months with a plan to follow patients
for 1 year. One Caucasian patient was recruited for ev-
ery 4 racial or ethnic minorities consented. Of the 5
centers identified, only 3 were able to open the study
for enrollment. Both centers that failed to open the
study had coordination issues when personnel who
were trained in the recruitment of patients changed
prior to start of the study. Such changes in study coor-
dination staff are a common occurrence, and this pos-
sibility should be anticipated when designing study
processes. Tables 2a and 2b show the actual number
of patients recruited for this study, and the pro-
jected number of patients who can potentially be
enrolled if the study were extended to more centers
and conducted over a longer study period. These
numbers do not include potential loss to follow-up
over time.
Although the participation rate is remarkably high,
100% at baseline, information obtained from patients
at 6 months and 1 year dramatically decreased to less
than 60%. Although most patients continued to be
seen by the transplant centers and information regard-
ing posttransplant eventswere recorded for clinical and
research purposes, obtaining longitudinal information
on survey instruments from patients proved challeng-
ing. This is partly because of different follow-up prac-
tices used by centers and the level of coordination
between the clinical and research coordinators. A po-
tential solution to this problemwould utilize a centrally
located coordinating center in charge of sending fol-
low-up questionnaires. However, the IRBs of the cen-
ters participating in this study did not allow their
patients to be contacted in person by a third party given
the current laws regarding patient confidentiality. A
strong case for having a central coordinating center re-
sponsible for processing and following up survey ques-
tionnaires, in retrospect, should had been made.
Investigators should devote enough time to consult
with IRBs of participating centers to identify how
best to utilize a central coordinating center, but main-
tain utmost patient confidentiality. This approach may
have prevented 2 issues that caused decreased data col-
lection over time: (1) inattention from clinicalTable 2a. Actual 6 Month Accrual
Center 1 Center 2 Center 3 Total
Median number
of allotransplants/ year
20 50 200
Ethnic minorities enrolled 5 8 9 22
Caucasian enrolled 1 2 2 5
Refusal 0 0 0 0coordinatorswho are busy taking care of themedical is-
sues, and (2) failure to collect and process data in
a timely fashion, preventing implementation of correc-
tive actions in real time. However, centralization of
data processing should be combined with close com-
munication between the coordinator from the recruit-
ing center and the patients so that the close relationship
between the treating center and patient is harnessed
into participation and study retention.
Data Collection
Some of the logistic difficulties with obtaining data
over time were discussed in the previous section. This
section will discuss the feasibility of collecting diverse
types of information that are not normally collected
for clinical or research purposes.
One of the most commonly hypothesized reasons
for disparity in outcome by race and ethnicity is
disparate income. Although census-based income
approximation inferred from residential ZIP codes or
address level analysis are commonly utilized with vary-
ing accuracy, these methods do not accurately reflect
the actual total household income of patients, and is
therefore subject to limitations. Patient income is
not usually collected by transplant centers, and, if
collected, is not incorporated into the medical records.
Direct ascertainment of income from the patient may
be themost accurateway to obtain these data. As shown
in Table 3, approximately 20% of patients in the study
did not report information regarding their income, ei-
ther as a definite amount in dollars or as a range. If ac-
curate and complete data cannot be collected, this has
profound implications in addressing the role of socio-
economic status on outcomes of racial or ethnicminor-
ities. Information about health care insurance plan
details of the patients also proved difficult to gather. Al-
though patients are able to report the type of insurance
they have, 47% of the patients in the study were not
able to provide details about their copayments, or
amount of monthly premiums. If these data are
critical to an analysis, an alternative plan on how to
obtain them is warranted. For instance, data on income
may best be collected during a routine psychosocial in-
terview by a social worker prior to transplant when
Table 3. List of Data Collected and Their Respective Com-
pletion Rates in Percent
Data Collected
Racial Ethnic
Minorities Caucasians
Self-reported race/ ethnicity 100 100
Age at transplant in years (range) 100 100
Sex 100 100
Place of residence (rural versus urban) 84 100
Marital status 95 100
Born in the U.S. 100 100
Knowledge of English 100 100
Education 100 100
Socialeconomic
work status 95 60
Median annual personal income (specified), K 79 80
Median family income (specified), K 74 80
Personal income in range 79 60
Have enough money for living expenses 95 100
Patient’s role in family 89 80
Residence within 1 hour of transplant center 100 100
Insurance data
Health insurance type provided 100 100
Coinsurance rates/copayment amounts 53 80
Provided monthly health insurance premiums 53 80
Prescription drugs covered 74 80
Social-cultural/spiritual/religiosity
Patient’s point of view about decision making 84 100
Family’s role in decision making 95 100
Religion 95 100.
Believe illness is caused by God 95 100
Recovery because of God’s will 100 100
Recovery because of MD’s knowledge 95 100
Is patient religious? 95 60
Praying frequency 100 100
Church-going frequency 100 100
How ‘‘spiritual’’ the patient is 95 100
FACT spiritual 12 89 80
Social support
Medical outcomes study social support
survey
100 100
Patient satisfaction
Completed PSQ-18 (Patient Satisfaction
Questionnaire)
89 100
Biol Blood Marrow Transplant 15:903-909, 2009 907Study Design Considerations in Ethnic Minority Disparity in HCTfinancial needs are discussed. Insurance information
may best be obtained from people in charge of securing
insurance clearance prior to transplant, or review of the
plan language. The expectation formissing data should
therefore be considered in the statistical analyses, in-
cluding power calculations. Plans formultivariate anal-
yses should specify how missing data will be handled
and the potential of these missing data to contribute
bias to the results. Plans for sensitivity analyses may
also need to be specified.
Surprisingly, although income and insurance data
were hard to collect, other potentially sensitive socio-
demographic information collected at baseline was
more complete. Questions addressing sociodemo-
graphic characteristics, sociocultural aspects of medi-
cal decision making, belief systems, level of
religiosity and spirituality, and other psychometric in-
struments measuring social support, patient satisfac-
tion, and general adherence to medical regimens
were obtained with an acceptable 5% to 10% missing
data rate.IRB Issues
Any study focused on racial or ethnic minorities
appears to trigger increased scrutiny from IRBs. In-
creased sensitivity regarding how racial or ethnic mi-
norities have been treated in historic clinical trials
may explain some of this discrepancy, as does their
role as a ‘‘special population.’’ However, this appears
to have led to a surprising degree of inconsistency in
the recommendations arising from different IRBs re-
garding the study conduct. For example, the original
protocol stipulated that the questionnaire would be
translated into Spanish with the hope of increasing
Hispanic participation. It was interesting to discover
that this can be viewed as preferential treatment of 1
racial or ethnic group over another and was perceived
as a violation of equity. Although this concern did not
prevent the study from opening, additional protocol
changes were required. In a multicenter setting where
a harmonized protocol is desired, the need to individ-
ualize protocols for each center adds time and coordi-
nator costs. IRBs also varied greatly in their activation
speed, with the interval between submission and ap-
proval ranging from 2 months to 6 months. In retro-
spect, it is interesting to note that achieving IRB
approval to open a multicenter clinical trial of an ex-
perimental drug may be easier than to execute an ob-
servational study dealing with disparity according to
race and ethnicity. Many institutions and IRBs ap-
peared unfamiliar with disparity studies and applied
different criteria in their reviews. Familiarity with
these criteria during the study design phase might
have addressed issues that delayed the timely start
and completion of the study.Personnel Issues
The funding for this feasibility study allowed us to
invite all study coordinators from the 5 participating
centers to come to a central location for training.
Topics included review of the protocol, the subject re-
cruitment and consent procedures, the sampling
framework for the study, the use of necessary tracking
tables, and the data forms. The discussion allowed
questions to be clarified and facilitated camaraderie
and relationship development among the participating
centers. The funding did not, however, cover any sal-
ary support for any personnel involved in the different
centers. It took another 6 months from the initial
meeting of the study coordinators to finally get the
study started in 1 center after securing IRB approvals.
Centers 2 and Center 3 followed after another
6 months. Patients were followed for 12 months, and
data were obtained and processed for a total of
12months. After 5 years ofmeetings, securing funding,
study coordination, IRB approvals, patient recruit-
ment, patient follow-up, and data form processing,
we completed this feasibility study.
908 Biol Blood Marrow Transplant 15:903-909, 2009F. R. Loberiza Jr. et al.Within those 5 years, the main principal investiga-
tor (PI) changed institutions and relegated the IRB re-
lated and data management tasks to another PI, who
also changed institutions halfway through the study.
A study coordinator in 1 center, who trained for the
study and was responsible for recruiting patients, had
to take a medical leave. This prevented the study
from even starting at that center as there were no other
substitute personnel who could perform the needed
tasks. The PI of another institution changed affilia-
tions prior to start of the study, and, therefore, the in-
frastructure that allowed recruitment of patients at
that center was lost.COMMENTS
This feasibility study was able to recruit a diverse
group of racial or ethnic minorities in the setting of al-
logeneic HCT, with a high initial participation rate.
Although it is possible to study disparity between
Whites and non-Whites (a grouped category of all mi-
norities) and its causes, it may not be possible to study
specific racial or ethnic groups, for instance African
Americans, Hispanics, or Asians compared with Cau-
casians because of limited numbers. A study focused
on 1 racial or ethnic group is likely to suffer from inad-
equate statistical power, unless the differences between
groups are large. One possible solution is to use other
outcomes that are known to differ widely by race or
ethnicity (at least in other disease models), like medical
service utilization, or perhaps rehospitalization. The
ability to track these alternative outcomes needs to
be defined well to prevent ascertainment bias prior to
conducting a large-scale multicenter study. Mecha-
nisms to optimize continued participation also appear
valuable.
This feasibility study also showed that socioeco-
nomic data may need to be obtained from multiple
sources. A considerable number of patients may not
volunteer information on income, at least in the con-
text of research, but may be willing to divulge this in-
formation in the context of psychosocial evaluation by
a social worker. Considering the amount of potential
missing information on income, this would have pro-
found implications in the analyses of studies, because
income has been implicated rather consistently as a po-
tential contributor to any disparities in outcomes.
Other types of data (psychologic, cultural, religiosity,
or spirituality) can be obtained in this test population
with a high degree of completion. The potential for
IRB-related delays in study initiation must be consid-
ered when planning a large study on disparity by race
or ethnicity in HCT. A main coordinating center
should help integrate all IRB requirements as part of
study planning and achieve a second critical objectiveof better data tracking and processing. This may im-
prove the ability to collect patient-derived information
during the follow-up phase of the study.
Finally, the goal of racial and ethnic studies is to
identify modifiable factors causing differences in out-
come. Once identified, successful interventions to ad-
dress these factors may ultimately improve survival of
minorities and narrow the disparity gap. This perspec-
tive focuses less on biologic determinants of outcome,
for example, disease stage and HLA-matching, which
might not be improved, and instead tries to sort out
complex factors tied to race and ethnicity, which affect
the success of HCT. Despite the difficulty in conduct-
ing disparity studies in racial and ethnic minorities,
such studies are essential to ensure that people of all
ethnic and racial backgrounds have the best chance
possible of benefiting from HCT.ACKNOWLEDGMENTS
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